Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service aneurysm & intracranial embolization cases in New Jersey: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 13% on average (82 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 6 | 237 | 33% |
| 2020 | 6 | 255 | 36% |
| 2021 | 9 | 302 |
Aneurysm coiling and flow diversion, AVM and tumor embolization, intracranial stenting. Professional codes (what the surgeon bills): CPT 61624, 61635, 61630.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 82% of the cases CMS names in New Jersey; 10 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 25 | 1,148+12%/yr | +12%/yr | 0.6 | 0% | 1,980 in 2030+9.5%/yr |
| Pennsylvania | 29 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Stroke thrombectomy | 15 | 346+3.2%/yr | +3.2%/yr | 0.30.7× | 0% | 330 in 2030−1%/yr |
| DBS & VNS |
Aneurysm & intracranial embolization in every state, and its device makers · Every procedure market in New Jersey · Every state · Compare with New York
| 2024 |
| 399 |
| 45% |
| 2025 est. | ≈ 400 | – |
| 2026 est. | ≈ 430 | – |
| 39% |
| 2022 | 10 | 333 | 41% |
| 2023 | 11 | 341 | 43% |
| 2024 | 13 | 399 | 45% |
| 2025 from claims | – | 397 321–466 | 46% |
| 2026 forecast | – | 432 339–543 | 46% |
| 2027 forecast | – | 470 348–621 | 47% |
| 2028 forecast | – | 511 361–705 | 47% |
| 2029 forecast | – | 555 377–795 | 47% |
| 2030 forecast | – | 603 395–894 | 48% |
In 2025, 100% inpatient hospital.
| Forecast, Medicare FFS | Inpatient |
|---|---|
| 2026 · ~430 | ~430 |
| 2027 · ~470 | ~470 |
| 2028 · ~510 | ~510 |
The forecast’s cases at the projected mix.
The mix is steady: the trend moves no setting by a point or more by 2028.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| 803+20%/yr |
| +20%/yr |
| 0.6 |
| 0% |
| 1,470 in 2030+11%/yr |
| Massachusetts | 13 | 456+8%/yr | +8%/yr | 0.5 | 0% | 820 in 2030+10%/yr |
| Connecticut | 6 | 214+31%/yr | +31%/yr | 0.6 | 0% | 330 in 2030+7.6%/yr |
| 4 |
| 206+7.7%/yr |
| +7.7%/yr |
| 0.20.7× |
| 0% |
| 280 in 2030+5.4%/yr |
| CSF shunts | 0 | 134−11%/yr | −11%/yr | 0.10.6× | 0% | 120 in 2030−1.3%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Medtronic leads with 32% of company spending on these surgeons in 2025, +20 pts on 2024.
In 2025, 9 companies reported engagement with New Jersey’s surgeons worth $155K in consulting, speaking, meals and travel tied to these products, about $12K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.